Results 121 to 130 of about 570,572 (255)

Emergency catheter ablation in critical patients

open access: yesJournal of Emergencies, Trauma and Shock, 2010
Emergency catheter ablation is justified in critical patients with drug-refractory life-threatening arrhythmias. The procedure can be used for ablation of an accessory pathway in preexcitation syndrome with high risk of ventricular fibrillation and in ...
Tebbenjohanns Jurgen, Ruhmkorf Klaus
doaj  

Clinical characteristics of the 2 probands (CPVT: Cathecolaminergic Polymorphic Ventricular Tachycardia; VF: idiopathic ventricular fibrillation; LQTS: Long QT Syndrome; SCD: sudden cardiac death; VE: ventricular extrasystole).

open access: yes, 2016
Clinical characteristics of the 2 probands (CPVT: Cathecolaminergic Polymorphic Ventricular Tachycardia; VF: idiopathic ventricular fibrillation; LQTS: Long QT Syndrome; SCD: sudden cardiac death; VE: ventricular extrasystole).
Rosa Macías-Ruiz (489478)   +11 more
core   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul   +13 more
wiley   +1 more source

Successful prehospital double sequential external defibrillation in a 15-year-old with hypertrophic cardiomyopathy

open access: yesResuscitation Plus
We present the case of a 15-year-old boy with hypertrophic cardiomyopathy who suffered out-of-hospital cardiac arrest. After failure of conventional defibrillation to terminate refractory ventricular fibrillation, double sequential external ...
F. Weilbacher   +6 more
doaj   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao   +27 more
wiley   +1 more source

EXPERIENCE OF MANAGEMENT OF THE PATIENT WITH THE RESYNCHRONIZATION BIVENTRICULAR PACING WITHOUT DESTRUCTION OF ATRIO-VENTRICULAR NODE SUFFERING FROM CHRONIC HEART FAILURE AND PERMANENT ATRIAL FIBRILLATION

open access: yesJournal of V. N. Karazin Kharkiv National University: Series Medicine, 2013
The case of cardiac biventricular resynchronization without destruction of the atrio-ventricular node in patients with chronic heart failure (CHF) and permanent atrial fibrillation (AF) is described. The observation period was 14 months.
I. V. Shanina, D. E. Volkov, D. A. Lopin
doaj  

Characterizing nonlinearity in Ventricular Fibrillation

open access: yes, 1999
We apply techniques from nonlinear dynamical systems theory to determine whether Ventricular Fibrillation (VF) comes from a stochastic, or a more complex nonlinear process.
Robertson, C.   +6 more
core  

Isolated focus of ventricular fibrillation.

open access: yes, 2009
Mechanisms underlying the initiation of ventricular tachycardia have been described as either rapidly firing focus initiated by triggered activity or automaticity, or a reentrant wavefront initiated by a premature ventricular depolarization.
Haïssaguerre, Michel   +3 more
core   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié   +5 more
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy